Rodman & Renshaw analyst Brandon Folkes initiated coverage of Eupraxia Pharmaceuticals (EPRX) with a Buy rating and $9 price target
Rodman & Renshaw analyst Brandon Folkes initiated coverage of Eupraxia Pharmaceuticals (EPRX) with a Buy rating and $9 price target